Cargando…
Microfluidic Platforms for High-Throughput Pancreatic Ductal Adenocarcinoma Organoid Culture and Drug Screening
Pancreatic Ductal Adenocarcinoma (PDAC), the most common pancreatic cancer type, is believed to become the second leading cause of cancer-related deaths by 2030 with mortality rates of up to 93%. It is often detected at a late stage due to lacking symptoms, and therefore surgical removal of the tumo...
Autores principales: | Geyer, Marlene, Queiroz, Karla |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8733732/ https://www.ncbi.nlm.nih.gov/pubmed/35004672 http://dx.doi.org/10.3389/fcell.2021.761807 |
Ejemplares similares
-
Editorial: Translational Insights Into Pancreatic Ductal Adenocarcinoma
por: Bijlsma, Maarten F., et al.
Publicado: (2022) -
Pancreatic Ductal Adenocarcinoma: Preclinical in vitro and ex vivo Models
por: Gündel, Beate, et al.
Publicado: (2021) -
KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression
por: Zhang, Zining, et al.
Publicado: (2023) -
GATA4 Regulates Inflammation-Driven Pancreatic Ductal Adenocarcinoma Progression
por: Jiang, Weiliang, et al.
Publicado: (2021) -
Tumor-Associated Macrophages in Pancreatic Ductal Adenocarcinoma: Origin, Polarization, Function, and Reprogramming
por: Yang, Sen, et al.
Publicado: (2021)